The prognostic role of KRAS mutations in stage I CRC was previously investigated in two studies that showed that mutations in this gene are associated with shorter overall survival and recurrence-free survival [6, 18], while the specific prognostic role of PIK3CA mutations in stage I CRC had not been analyzed thus far. This evidence concerns the gene PIK3CA and colorectal carcinoma.